These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16227815)

  • 1. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.
    Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL; Slama L; Lukiana T; Jaillon P; Pialoux G
    AIDS; 2005 Nov; 19(16):1937-8. PubMed ID: 16227815
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
    Guiard-Schmid JB; Poirier JM; Bonnard P; Meynard JL
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):393-4; author reply 394. PubMed ID: 16540944
    [No Abstract]   [Full Text] [Related]  

  • 3. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
    Furtek KJ; Crum NF; Olson PE; Wallace MR
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
    Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
    J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A
    AAPS J; 2013 Apr; 15(2):308-15. PubMed ID: 23224752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
    D'Avolio A; Carcieri C; Cusato J; Simiele M; Calcagno A; Allegra S; Sciandra M; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2014 Nov; 69(11):3061-6. PubMed ID: 24997317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
    Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
    HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.
    Goicoechea M; Best B; Capparelli E; Caperna J; Ballard C; Haubrich R
    AIDS; 2006 Oct; 20(16):2127-8. PubMed ID: 17053363
    [No Abstract]   [Full Text] [Related]  

  • 20. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.